Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. 1999

M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
Division of Carcinogenesis, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) and/or their receptors are increasingly detected in solid human tumors, although little is known about their function in tumor growth and invasion. We analyzed RNA and protein expression of both factors and their receptors in 22 human gliomas (WHO grade II, III, and IV) and derived cell cultures. G-CSF, GM-CSF, and/or their receptors were expressed in all tumors and derived cell cultures, but coexpression of both factors and receptors was almost exclusively found in grade IV glioblastomas and thus correlated with advanced tumor stage. The functional significance of G-CSF and GM-CSF as regulators for glioma cells was demonstrated by 1) stimulation of proliferation and migration in tumor cells expressing one or both receptors by the corresponding factor; 2) inhibition of growth and migration of glioma cells expressing G-CSF, GM-CSF, and their receptors by neutralizing antibodies to both factors. These results indicate a significant role for both factors in the autocrine regulation of growth and migration in late-stage malignant gliomas and suggest a shift from paracrine to autocrine regulation with tumor progression. The implication of G-CSF and GM-CSF in glioblastoma growth regulation could make these factors further prognostic indicators and raises questions concerning their use in cancer therapy.

UI MeSH Term Description Entries
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D016178 Granulocyte-Macrophage Colony-Stimulating Factor An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. CSF-GM,Colony-Stimulating Factor, Granulocyte-Macrophage,GM-CSF,Histamine-Producing Cell-Stimulating Factor,CSF-2,TC-GM-CSF,Tumor-Cell Human GM Colony-Stimulating Factor,Cell-Stimulating Factor, Histamine-Producing,Colony Stimulating Factor, Granulocyte Macrophage,Granulocyte Macrophage Colony Stimulating Factor,Histamine Producing Cell Stimulating Factor,Tumor Cell Human GM Colony Stimulating Factor
D016179 Granulocyte Colony-Stimulating Factor A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. Colony-Stimulating Factor, Granulocyte,G-CSF,Myeloid Growth Factor,Colony Stimulating Factor, Granulocyte,Factor, Granulocyte Colony-Stimulating,Factor, Myeloid Growth,Granulocyte Colony Stimulating Factor,Growth Factor, Myeloid
D016187 Receptors, Granulocyte-Macrophage Colony-Stimulating Factor Receptors that bind and internalize the granulocyte-macrophage stimulating factor. Their MW is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor. Antigens, CD116,CD116 Antigens,GM-CSF Receptors,CD116 Antigen,GM-CSF Receptor,Receptor, Granulocyte-Macrophage Colony-Stimulating Factor,Receptors, GM-CSF,Antigen, CD116,GM CSF Receptor,GM CSF Receptors,Receptor, GM-CSF,Receptor, Granulocyte Macrophage Colony Stimulating Factor,Receptors, GM CSF,Receptors, Granulocyte Macrophage Colony Stimulating Factor
D016188 Receptors, Granulocyte Colony-Stimulating Factor Receptors that bind and internalize GRANULOCYTE COLONY-STIMULATING FACTOR. Their MW is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells. G-CSF Receptors,G-CSF Receptor,Granulocyte Colony-Stimulating Factor Receptors,Receptor, Granulocyte Colony-Stimulating Factor,Receptors, G-CSF,G CSF Receptor,G CSF Receptors,Granulocyte Colony Stimulating Factor Receptors,Receptor, G-CSF,Receptor, Granulocyte Colony Stimulating Factor,Receptors, G CSF,Receptors, Granulocyte Colony Stimulating Factor
D016543 Central Nervous System Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges. CNS Neoplasm,CNS Neoplasms,Central Nervous System Neoplasm,Central Nervous System Tumor,Neoplasms, Central Nervous System,Primary Central Nervous System Neoplasm,Central Nervous System Neoplasms, Primary,Central Nervous System Tumors,Primary Central Nervous System Neoplasms,Tumors, Central Nervous System,Neoplasm, CNS,Neoplasms, CNS

Related Publications

M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
March 2012, Cytokine,
M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
July 1993, Blood,
M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
November 2004, Cancer research,
M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
November 2006, The Annals of thoracic surgery,
M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
November 1996, Annals of hematology,
M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
April 1989, Seminars in hematology,
M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
September 1989, Proceedings of the National Academy of Sciences of the United States of America,
M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
January 1989, Biotechnology therapeutics,
M M Mueller, and C C Herold-Mende, and D Riede, and M Lange, and H H Steiner, and N E Fusenig
July 1992, The New England journal of medicine,
Copied contents to your clipboard!